NCT03282851View on ClinicalTrials.gov

Pharmacokinetics/Pharmacodynamics (PK/PD) Equivalence Study of MSB11456

PHASE1CompletedINTERVENTIONAL
Enrollment

696

Participants

Timeline

Start Date

November 27, 2017

Primary Completion Date

October 1, 2019

Study Completion Date

October 1, 2019

Conditions
Healthy
Interventions
DRUG

MSB11456

Subjects will receive a single injection of MSB11456 on Day 1.

DRUG

US-licensed Actemra

Subjects will receive a single injection of US-licensed actemra on Day 1.

DRUG

EU-approved RoActemra

Subjects will receive a single injection of EU-approved RoActemra on Day 1.

Trial Locations (2)

Unknown

Research site, Auckland

Research site, Christchurch

All Listed Sponsors
lead

Fresenius Kabi SwissBioSim GmbH

INDUSTRY

NCT03282851 - Pharmacokinetics/Pharmacodynamics (PK/PD) Equivalence Study of MSB11456 | Biotech Hunter | Biotech Hunter